New investigator-initiated research could help revive Pfizer's acute myeloid leukaemia (AML) treatment, Mylotarg (gemtuzumab ozogamicin), following the withdrawal of the product last year.
The company pulled the ten-year old drug after the FDA said that a post-marketing study showed a higher death rate...